NuCana plc Sponsored ADR NCNA 深 滬
等待開盤 03-26 09:30:00 美东时间
1.53
-0.060
-3.77%
華盛通- 最 高1.5796
- 今 開1.55
- 成交量 15.22万股
- 最 低 1.42
- 昨 收 1.59
- 總市值 636.77万
- 52周最高 250.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.42
- 委 比 67.48%
- 總股本 416.19万
- 歷史最高 160000.00
- 量 比 3.24
- 振 幅 10.04%
- 歷史最低 1.42
- 每 手 1
- 風險率 50.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多NuCana shares are trading lower. The company reported Q4 financial results.
NuCana shares are trading lower. The company reported Q4 financial results.
03-20 19:52
Clearpoint Neuro, Valneva, Rocket Lab And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Dow futures up 200 points, ClearPoint Neuro (CLPT) stock falls after wider-than-expected quarterly loss. Other stocks moving lower in pre-market.
03-18 20:02
NuCana appoints Theresa Bruce as chief operating officer
NuCana (NCNA) announced on Tuesday the appointment of Theresa Bruce as chief operating officer, effective January 1, 2026. Bruce previously served as chief operating officer at Nexus Oncology and has ...
01-06 22:08
NuCana Appoints Theresa Bruce COO, Effective Jan. 1
NuCana plc (NASDAQ: NCNA) ("NuCana" or the "Company"), a clinical-stage biopharmaceutical company focused on improving treatment outcomes for patients with cancer, announced the appointment of Theresa Bruce as Chief
01-06 21:01
NuCana Appoints Theresa Bruce as Chief Operating Officer
NuCana plc has appointed Theresa Bruce as Chief Operating Officer, effective January 1, 2026. With over 25 years of experience in oncology R&D, Bruce will lead the advancement of NuCana's pipeline, including the Phase 1/2 expansion study of NUC-7738 in melanoma and the further development of NUC-3373. Bruce previously served as Senior Vice President of Clinical Operations at NuCana and brings extensive expertise in clinical development. NuCana fo...
01-06 13:00
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
NuCana plc presented clinical data at the 2025 ESMO Immuno-Oncology Congress showing continued activity of NUC-7738 in combination with pembrolizumab for PD-1 inhibitor-resistant metastatic melanoma. Results included two partial responses, seven stable disease cases, and no new safety signals. These findings support the potential benefit of NUC-7738 for patients with advanced melanoma, with further enrollment and clinical advancement planned.
2025-12-10 13:00
NuCana GAAP EPS of £0.00
NuCana press release (NCNA): Q3 GAAP EPS of £0.00. NuCana reported a net loss of £0.3 million for the quarter ended September 30, 2025, which includes other income of £2.7 million, as compared to a ne...
2025-11-14 05:54
NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
NuCana plc announced positive data for its anti-cancer medicines NUC-7738 and NUC-3373, supporting their potential to improve treatment outcomes. Initial data from the expansion study of NUC-7738 is expected in Q4 2025, with final data in 2026. The company is well-capitalized, with cash runway into 2029. NuCana reported a net loss of £0.3 million for Q3 2025 and £26.9 million for the first nine months, but raised £38.4 million via its ATM program...
2025-11-13 21:01
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
NuCana plc announced that China's National Intellectual Property Administration granted a key patent for NUC-7738, a novel anti-cancer agent in Phase 1/2 clinical trials for melanoma. This patent strengthens the company's global intellectual property strategy and supports innovative cancer therapies in China. NUC-7738, which disrupts RNA polyadenylation, is being studied in combination with pembrolizumab.
2025-11-05 13:00
